Unknown

Dataset Information

0

Cognitive decline in Parkinson's disease is associated with reduced complexity of EEG at baseline.


ABSTRACT: Parkinson's disease is a neurodegenerative disorder requiring motor signs for diagnosis, but showing more widespread pathological alterations from its beginning. Compared to age-matched healthy individuals, patients with Parkinson's disease bear a 6-fold lifetime risk of dementia. For individualized counselling and treatment, prognostic biomarkers for assessing future cognitive deterioration in early stages of Parkinson's disease are needed. In a case-control study, 42 cognitively normal patients with Parkinson's disease were compared with 24 healthy control participants matched for age, sex and education. Tsallis entropy and band power of the ?, ?, ?, ? and ?-band were evaluated in baseline EEG at eyes-open and eyes-closed condition. As the ?-band showed the most pronounced differences between Parkinson's disease and healthy control groups, further analysis focussed on this band. Tsallis entropy was then compared across groups with 16 psychological test scores at baseline and follow-ups at 6?months and 3?years. In group comparison, patients with Parkinson's disease showed lower Tsallis entropy than healthy control participants. Cognitive deterioration at 3?years was correlated with Tsallis entropy in the eyes-open condition (P?

SUBMITTER: Keller SM 

PROVIDER: S-EPMC7749793 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cognitive decline in Parkinson's disease is associated with reduced complexity of EEG at baseline.

Keller Sebastian M SM   Gschwandtner Ute U   Meyer Antonia A   Chaturvedi Menorca M   Roth Volker V   Fuhr Peter P  

Brain communications 20201127 2


Parkinson's disease is a neurodegenerative disorder requiring motor signs for diagnosis, but showing more widespread pathological alterations from its beginning. Compared to age-matched healthy individuals, patients with Parkinson's disease bear a 6-fold lifetime risk of dementia. For individualized counselling and treatment, prognostic biomarkers for assessing future cognitive deterioration in early stages of Parkinson's disease are needed. In a case-control study, 42 cognitively normal patient  ...[more]

Similar Datasets

| S-EPMC4842380 | biostudies-literature
| S-EPMC7853194 | biostudies-literature
| S-EPMC7864432 | biostudies-literature
| S-EPMC8636132 | biostudies-literature
| S-EPMC5763317 | biostudies-literature
| S-EPMC7380054 | biostudies-literature
| S-EPMC3323737 | biostudies-literature
| S-EPMC8410800 | biostudies-literature
| S-EPMC6877592 | biostudies-literature
| S-EPMC4825674 | biostudies-literature